Results 1-20 of 1,541 for drugs speaker:Stephen Donnelly

Written Answers — Department of Health: Programme for Government (9 Sep 2024)

Stephen Donnelly: ...Care. Goals in this section are grouped under seven headings: Delivery of Care in a COVID-19 Environment Sláintecare Promoting Women's Health Healthier Future Mental Health Health-led Approach to Drugs Misuse Age-Friendly Ireland Information on progress towards implementing these commitments is set out at the following link, under the seven aforementioned headings.

Written Answers — Department of Health: Departmental Schemes (9 Sep 2024)

Stephen Donnelly: ...; diabetes mellitus; parkinsonism; epilepsy; phenylketonuria; haemophilia; spina bifida; hydrocephalus; and conditions arising from the use of Thalidomide. Under the LTI Scheme, patients receive drugs, medicines, and medical and surgical appliances directly related to the treatment of their illness, free of charge. While there are currently no plans to extend the list of conditions, it is...

Written Answers — Department of Health: Healthcare Policy (9 Sep 2024)

Stephen Donnelly: ...may also choose to address their symptoms through other means, including lifestyle changes. Currently many women receive support in accessing HRT medication under the General Medical Services (GMS) Scheme or under the Drug Payment Scheme. However, I have asked my officials to explore the options available in relation to the provision of state-funded HRT to all women who require it in...

Written Answers — Department of Health: Patient Transport (9 Sep 2024)

Stephen Donnelly: The Health Service Executive (HSE) administers two schemes, on behalf of the state, which assist people with their medical costs. These are the General Medical Services (GMS) Scheme, and the Drug Payment Scheme (DPS). People who cannot, without undue hardship, arrange for the provision of medical services for themselves and their dependants may be eligible for a medical card under the GMS...

Written Answers — Department of Health: Vaccination Programme (9 Sep 2024)

Stephen Donnelly: ...to keep abreast of changes in the patterns of disease. Therefore, the immunisation schedule will continue to be amended over time. The shingles vaccine is not available through the medical card or drug payment scheme. Shingles vaccination is not currently provided as part of the national immunisation programme. Further information is available here: www2.hse.ie/conditions/shingles/ It is...

Written Answers — Department of Health: Medicinal Products (9 Sep 2024)

Stephen Donnelly: ...Regulatory Authority (HPRA). They have never been on the formal GMS Reimbursement List. However, the product is available on an exceptional basis under Discretionary Hardship Arrangements and the Drugs Payment Scheme (DPS).

Written Answers — Department of Health: Healthcare Policy (9 Sep 2024)

Stephen Donnelly: ...; diabetes mellitus; parkinsonism; epilepsy; phenylketonuria; haemophilia; spina bifida; hydrocephalus; and conditions arising from the use of Thalidomide. Under the LTI Scheme, patients receive drugs, medicines, and medical and surgical appliances directly related to the treatment of their illness, free of charge. While there are currently no plans to extend the list of conditions, it is...

Written Answers — Department of Health: Assisted Human Reproduction (9 Sep 2024)

Stephen Donnelly: ...client’s nominated community pharmacy by the High Tech Hub managed by the Primary Care Reimbursement Service. The cost of the medicines is then covered, as appropriate, under the client’s eligibility, i.e., Medical Card or Drugs Payment Scheme. I want to reassure the Deputy that my Department and the Government are focused, through the full implementation of the Model of Care...

Written Answers — Department of Health: Medicinal Products (9 Sep 2024)

Stephen Donnelly: ...dispensing. These are as follows:At the request of a patient's physician.Due to the inherent nature of a medicinal product i.e. product stability and shelf life.Where a patient is commencing new drug therapy with a view to establishing patient tolerance and acceptability before continuing a full treatment regime.In exceptional circumstances where the patient is incapable of safely and...

Written Answers — Department of Health: Healthcare Policy (9 Sep 2024)

Stephen Donnelly: ...; diabetes mellitus; parkinsonism; epilepsy; phenylketonuria; haemophilia; spina bifida; hydrocephalus; and conditions arising from the use of Thalidomide. Under the LTI Scheme, patients receive drugs, medicines, and medical and surgical appliances directly related to the treatment of their illness, free of charge. While there are currently no plans to extend the list of conditions, it is...

Written Answers — Department of Health: Medicinal Products (9 Sep 2024)

Stephen Donnelly: ...terms of the specific details of the application for pricing and reimbursement of Fezolinetant (Veoza®) I have asked the HSE the current status of the pricing and reimbursement application of the drug and they have provided the following information: The HSE received an application for pricing / reimbursement on the 8th February 2024 from Astellas (the applicant) for Fezolinetant...

Written Answers — Department of Health: Departmental Bodies (10 Jul 2024)

Stephen Donnelly: In February 2023, I published the Mazars Review which examined the governance arrangements around the HSE’s Drug Pricing and Reimbursement Process. The Report found that the reimbursement process is operating in line with the legislation and that it is delivering results in line with international norms. I fully support the recommendations contained in the Mazars report around...

Written Answers — Department of Health: Medicinal Products (10 Jul 2024)

Stephen Donnelly: ..., and (g ) the terms of any agreement in place (whether entered into before, on or after the commencement of this section) between the Executive and any representative body of the suppliers of drugs, medicines or medicinal or surgical appliances where the agreement relates, whether directly or indirectly, to the price of the item.The 2013 Act and the IPHA Agreements (which are published)...

Written Answers — Department of Health: Medicinal Products (10 Jul 2024)

Stephen Donnelly: The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.

Written Answers — Department of Health: Medicinal Products (10 Jul 2024)

Stephen Donnelly: The Drug Payment Scheme (DPS) provides for the refund of the amount by which expenditure on approved prescribed medicines or medical and surgical appliances exceeds a named threshold in any calendar month. The DPS is not means tested and is available to anyone ordinarily resident in Ireland. The DPS threshold was reduced twice in 2022: From €114 to €100 per month on 1 January...

Written Answers — Department of Health: Medicinal Products (10 Jul 2024)

Stephen Donnelly: ...increase in demand; or product recalls due to potential quality issues. In February 2023 the Mazars Review was published which examined the governance arrangements around the HSE’s Drug Pricing and Reimbursement Process. The Report found that the reimbursement process is operating in line with the legislation and that it is delivering results in line with international norms....

Written Answers — Department of Health: Cannabis for Medicinal Use (10 Jul 2024)

Stephen Donnelly: I propose to take Questions Nos. 408 and 409 together. There are 10 products meeting the definition of "specified controlled drug" in S.I. 262/2019, the Misuse Of Drugs (Prescription And Control Of Supply Of Cannabis For Medical Use) Regulations 2019, however 2 products, made by Aurora, have not been brought to market by the manufacturer. There are 55 approved individuals on the MCAP...

Written Answers — Department of Health: Cannabis for Medicinal Use (10 Jul 2024)

Stephen Donnelly: A Ministerial Licence issued pursuant to Section 14 of the Misuse of Drugs Act 1977, entitles the clinician licensee to prescribe, import, supply, possess and administer a cannabis-based product containing Tetrahydrocannabinol. To date 372 Ministerial Licences have been issued to clinicians for the treatment of 77 different patients. Currently 28 patients are being treated under the programme.

Seanad: Health (Miscellaneous Provisions) Bill 2024: Committee and Remaining Stages (9 Jul 2024)

Stephen Donnelly: ...more complex areas, and if OST happened to be one of those, that can already be expanded under the Bill, as drafted, through secondary legislation. It would require an amendment to the Misuse of Drugs Act as well. There is more that needs to be done, but what the Senator is seeking to achieve with the amendment is already covered. It would be down to secondary legislation and expert...

Written Answers — Department of Health: Medicinal Products (9 Jul 2024)

Stephen Donnelly: ...the HSE and the Pharmaceutical Industry in relation to medicine pricing and reimbursement applications. CPU met with the applicant to discuss their application for Arachis hypogaea L., semen (peanuts) (Palforzia®). The Drugs Group is the national committee which the HSE has in place to make recommendations on the pricing and reimbursement of medicines. The membership of the HSE Drugs...